Full Press Release Details
Medical's Two-Fold Increase in September Unit Orders Demonstrates Impact of
Reports Increased Trend For August and September
Colo.--(BUSINESS WIRE)--Zynex Medical (OTCBB: ZYNX
pain management systems and electrotherapy products for medical patients with
functional disability, has significantly increased the number of monthly unit
orders since it expanded its sales force in July and August 2006.
unit orders increased to more than 250 during August and more than 300 in
September, from an average of approximately 150 units during the first seven
months of the year. The company believes this increase in sales and rentals
directly attributed to its recent addition of an experienced sales team skilled
in electrotherapy product sales.
additional sales representatives was an important milestone for Zynex Medical,"
said Thomas Sandgaard, President and Chief Executive Officer. "We are pleased,
but not surprised, that this expanded team is beginning to make a tremendous
impact on our sales and market penetration."
finalized its results for the third quarter of 2006, including the impact of
increased sales and rentals. Zynex will state these results in the Form 10-QSB
Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells
own design of electrotherapy medical devices in two distinct markets: standard
digital electrotherapy products for pain relief and pain management; and the
NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's
product lines are fully developed, FDA-cleared, commercially sold, and have
developed to uphold the Company's mission of improving the quality of life
patients suffering from impaired mobility due to stroke, spinal cord injury,
debilitating and chronic pain.
in this release are "forward-looking" and as such are subject to numerous risks
and uncertainties. Actual results may vary significantly from the results
expressed or implied in such statements. Factors that could cause actual results
to materially differ from forward-looking statements include, but are not
limited to, risks and delays associated with product development, risk of market
acceptance of products, technology or product obsolescence, competitive risks,
reliance on manufacturing partners, dependence on reimbursement from insurance
companies, additional capital needs and other risks described in our Form 10-KSB
for the year ended December 31, 2005.
Medical Holdings, Inc.